lifestyle.capitolhilltimes.com

Author: Protagonist Therapeutics

Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration

April 28, 2026
Protagonist Therapeutics Reports Granting of Inducement Awards

April 16, 2026
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting

March 30, 2026
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis

March 18, 2026
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis

March 18, 2026
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

February 25, 2026
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

February 25, 2026
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026

February 24, 2026
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026

January 7, 2026